STOCK TITAN
  1. Home
  2. Sec-filings
  3. ONC
  4. [8-K] BeOne Medicines Ltd. Reports Material Event

BeOne Medicines (ONC) faces RMB 446m China tax settlement hit in Q2

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

BeOne Medicines Ltd. reports the conclusion of a statutory tax audit in China that resulted in a settlement requiring an income tax payment of approximately RMB 446 million, including surcharges and related interest. The payment stems from agreed adjustments to previously filed tax returns and involves no administrative penalty.

The company indicates this income tax payment will be recognized in its U.S. GAAP financial statements for the second quarter of fiscal 2026. The disclosure follows earlier discussion of ongoing international tax audits that may lead to outcomes different from prior estimates because of complex local tax rules.

Positive

  • None.

Negative

  • None.

Insights

Large tax settlement in China creates a one-time charge and cash outflow.

BeOne Medicines has settled a Chinese statutory tax audit with an income tax payment of approximately RMB 446 million. This stems from adjustments to prior tax returns and will be reflected as an expense in the company’s U.S. GAAP results for Q2 fiscal 2026.

The company highlights that no administrative penalty was imposed, which confines the impact to tax, surcharge and interest amounts. Earlier disclosures referenced ongoing audits in jurisdictions outside the United States, underlining that complex local tax rules can make prior estimates less reliable.

Investors can focus on how this one-time payment affects reported net income and cash in the second quarter of fiscal 2026, and on any future updates about other tax audits mentioned in the company’s prior quarterly report.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
China tax settlement payment RMB 446 million Income tax, surcharges and related interest from statutory audit settlement
Recognition period Q2 fiscal 2026 Period when RMB 446 million tax payment will be recognized under U.S. GAAP
ADS share ratio 1 ADS = 13 ordinary shares American Depositary Shares listed on Nasdaq Global Select Market
statutory tax audit financial
"The Company recently concluded a statutory tax audit in China."
U.S. GAAP financial statements financial
"Such income tax payment is expected to be recognized in the Company’s U.S. GAAP financial statements"
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
American Depositary Shares financial
"American Depositary Shares, each representing 13 Ordinary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

FAQ

What did BeOne Medicines Ltd. (ONC) announce about its China tax audit?
BeOne Medicines Ltd. disclosed it has concluded a statutory tax audit in China. The company reached a settlement with the local tax authority requiring an income tax payment of about RMB 446 million, covering tax, surcharges and related interest, with no administrative penalty imposed.

How large is the tax payment BeOne Medicines must make after the China audit?
The settlement requires BeOne Medicines to make an income tax payment of approximately RMB 446 million. This amount includes surcharges and related interest arising from agreed adjustments to previously filed Chinese tax returns, and will be reflected as a one-time item in financial results.

When will BeOne Medicines recognize the RMB 446 million tax payment in its financials?
BeOne Medicines expects to recognize the RMB 446 million income tax payment in its U.S. GAAP financial statements for the second quarter of fiscal 2026. This means the charge will impact that quarter’s reported tax expense, net income and related financial metrics for investors.

Did the China tax settlement involve any penalties for BeOne Medicines Ltd.?
The company states that the settlement with the Chinese tax authority did not involve any administrative penalty. The payment of approximately RMB 446 million instead reflects income tax, surcharges and related interest tied to adjustments to previously filed tax returns, rather than punitive fines.

What ongoing tax risks has BeOne Medicines previously disclosed?
BeOne Medicines previously disclosed it is subject to ongoing tax audits outside the United States. The company noted that these audits may lead to liabilities materially different from current estimates because of uncertain and complex application of local tax regulations by certain foreign tax authorities.

What securities of BeOne Medicines are listed and where are they traded?
BeOne Medicines has American Depositary Shares listed on the Nasdaq Global Select Market under symbol ONC, each representing 13 ordinary shares. Its ordinary shares, with par value $0.0001 per share, are listed for trading on The Stock Exchange of Hong Kong Limited under stock code 06160.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0001651308false00016513082026-06-262026-06-26



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
Form 8-K
______________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): June 26, 2026

BEONE MEDICINES LTD.
(Exact Name of Registrant as Specified in Charter)

Switzerland
001-37686
98-1209416
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification Number)
c/o BeOne Medicines I GmbH
Aeschengraben 27
Basel 4051
Switzerland
(Address of Principal Executive Offices) (Zip Code)
+41 61 685 19 00
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share
ONC
The Nasdaq Global Select Market
Ordinary Shares, par value $0.0001 per share*
06160
The Stock Exchange of Hong Kong Limited
*Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 8.01. Other Events.

As previously disclosed in the Quarterly Report on Form 10-Q filed by BeOne Medicines Ltd. (the “Company”) with the Securities and Exchange Commission on May 6, 2026, the Company is subject to ongoing tax audits that may result in liabilities which could be materially different from current estimates due to the uncertain and complex application of local tax regulations by certain tax authorities outside of the United States.

The Company recently concluded a statutory tax audit in China. As a result of a settlement with the local tax authority, the Company agreed to certain adjustments to previously filed tax returns, which will result in an income tax payment (including surcharges and related interest) of approximately RMB 446 million. This settlement did not involve any administrative penalty. Such income tax payment is expected to be recognized in the Company’s U.S. GAAP financial statements for the second quarter of fiscal 2026.










SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BEONE MEDICINES LTD.
 
 
 
 
 
 
Date: June 26, 2026
By: 
/s/ Chan Lee        
 
Name:
Chan Lee
 
Title:
Senior Vice President, General Counsel


Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents